Core Viewpoint - The article highlights the recent funding and technological advancements of Shanghai Ruisi Health Technology Co., Ltd. (Ruisi Technology), focusing on its innovative solutions for myopia prevention and control among children and adolescents [2][4][6]. Company Overview - Ruisi Technology, established in 2017, specializes in myopia prevention for children and adolescents, utilizing AI-driven technologies that integrate artificial intelligence, optical engineering, and neuroscience [6]. - The company has developed proprietary technologies, including AI light-eye-brain neural regulation, and holds multiple intellectual properties, including 84 trademarks and 58 patents [6]. Recent Financing - On June 30, 2025, Ruisi Technology completed a multi-million A2 round of financing, led by Jinke Jun Chuang, with funds allocated for product development, medical device registration, and market expansion [2][11]. - Previous financing rounds include a 50 million RMB A round in December 2022 and a billion-level A+ round in March 2024, aimed at advancing clinical trials for myopia prevention products [11]. Product and Technology - Ruisi Technology's core products include the Vision Training Instrument D1 and MAX 2.0, which utilize advanced algorithms for real-time focus adjustment based on user needs [6][7]. - The company's far-view light screen product is a pioneering intelligent terminal for myopia prevention, employing digital defocus and AR technology [6][7]. Clinical Validation - Clinical studies have shown that Ruisi Technology's far-view light defocus digital technology significantly slows myopia progression, with a 50% reduction in eye axis elongation and an 80% decrease in myopia degree in trial groups [8]. - The company has established its products in over 400 cities across China and has partnered with over 600 professional institutions [8]. Industry Standards - Ruisi Technology has played a key role in setting industry standards, collaborating with Wenzhou Medical University to publish technical specifications for far-view electronic display terminals in June 2025 [8].

Core Viewpoint - The article highlights the innovative approach of Shanghai Ruisi Health Technology Co., Ltd. in integrating eye care products into the daily lives of children and adolescents, focusing on the prevention and control of myopia through advanced technology and clinical validation [3][12]. Company Overview - Ruisi Technology was established in 2017 and has developed AI-based optical brain nerve regulation technology, combining artificial intelligence, optical engineering, and clinical optometry to innovate in myopia management [3][5]. - The company has created a range of products, including the D1 vision training device and the Far Vision Light Screen PLUS 2.0, which utilize proprietary digital technology to provide personalized visual adjustments [5][8]. Clinical Validation - Multi-center clinical studies conducted by reputable institutions have shown that Ruisi's products significantly slow down the progression of myopia, with results indicating a 50% reduction in eye axis shortening and an 80% decrease in myopia degree in certain trials [8][9]. - The company has established a complete trust system from clinical data to academic certification, ensuring the long-term safety and effectiveness of its products [9]. Market Strategy and Future Plans - The recent funding will be directed towards two main areas: advancing medical qualifications through the registration of medical devices and enhancing technology and market reach [11]. - Ruisi aims to create a closed-loop service system that integrates detection, training, and feedback, targeting users aged 3 to 18 and expanding its presence across over 400 cities in China [11][12]. Industry Impact - Ruisi Technology plays a leading role in promoting industry standardization, having co-hosted the release of the first domestic standards for far vision technology, which aims to provide scientific backing for the industry [9][12]. - The company is positioned to address the high prevalence of myopia among children and adolescents in China, with significant social value and market potential [12].